Search research articles
Contact Us
Filters
Showing results (1-10 of 17) with videos related to
Page
of 2
Sort By:
Anti-Cancer Drugs
|
November 11, 2010
Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report
Sina Haftchenary, Miriam Avadisian, Patrick T Gunning
Molecular and Cellular Biochemistry
|
April 22, 2015
Signal transducer and activator of transcription 3 and 5 regulate system Xc- and redox balance in human breast cancer cells
Katja Linher-Melville, Sina Haftchenary, Patrick Gunning, et al.
The Journal of Biological Chemistry
|
October 8, 2014
Changes in signal transducer and activator of transcription 3 (STAT3) dynamics induced by complexation with pharmacological inhibitors of Src homology 2 (SH2) domain dimerization
Diana Resetca, Sina Haftchenary, Patrick T Gunning, et al.
Biophysical Chemistry
|
June 9, 2009
Binding interactions in early- and late-stage amyloid aggregates of TTR(105-115)
Yanfang Liang, Shohreh Zahedi Jasbi, Sina Haftchenary, et al.
Plos One
|
August 12, 2016
Chronic Inhibition of STAT3/STAT5 in Treatment-Resistant Human Breast Cancer Cell Subtypes: Convergence on the ROS/SUMO Pathway and Its Effects on xCT Expression and System xc- Activity
Katja Linher-Melville, Mina G Nashed, Robert G Ungard, et al.
ACS Medicinal Chemistry Letters
|
January 19, 2011
Identification of Purine-Scaffold Small-Molecule Inhibitors of Stat3 Activation by QSAR Studies
Vijay M Shahani, Peibin Yue, Sina Haftchenary, et al.
ACS Medicinal Chemistry Letters
|
October 18, 2023
Retraction of "Identification of Purine-Scaffold Small-Molecule Inhibitors of Stat3 Activation by QSAR Studies"
Vijay M Shahani, Peibin Yue, Sina Haftchenary, et al.
Bioorganic & Medicinal Chemistry
|
July 2, 2013
A 2,6,9-hetero-trisubstituted purine inhibitor exhibits potent biological effects against multiple myeloma cells
Vijay M Shahani, Daniel P Ball, Allan V Ramos, et al.
ACS Medicinal Chemistry Letters
|
September 24, 2015
Identification of Bidentate Salicylic Acid Inhibitors of PTP1B
Sina Haftchenary, Andriana O Jouk, Isabelle Aubry, et al.
Therapeutic Advances in Medical Oncology
|
March 2, 2023
Quality of life with ribociclib <i>versus</i> abemaciclib as first-line treatment of HR+/HER2- advanced breast cancer: a matching-adjusted indirect comparison
Hope S Rugo, Victoria Harmer, Joyce O'Shaughnessy, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 17) with videos related to
Sort By:
Page
of 2
Anti-Cancer Drugs
|
November 11, 2010
Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report
Sina Haftchenary, Miriam Avadisian, Patrick T Gunning
Molecular and Cellular Biochemistry
|
April 22, 2015
Signal transducer and activator of transcription 3 and 5 regulate system Xc- and redox balance in human breast cancer cells
Katja Linher-Melville, Sina Haftchenary, Patrick Gunning, et al.
The Journal of Biological Chemistry
|
October 8, 2014
Changes in signal transducer and activator of transcription 3 (STAT3) dynamics induced by complexation with pharmacological inhibitors of Src homology 2 (SH2) domain dimerization
Diana Resetca, Sina Haftchenary, Patrick T Gunning, et al.
Biophysical Chemistry
|
June 9, 2009
Binding interactions in early- and late-stage amyloid aggregates of TTR(105-115)
Yanfang Liang, Shohreh Zahedi Jasbi, Sina Haftchenary, et al.
Plos One
|
August 12, 2016
Chronic Inhibition of STAT3/STAT5 in Treatment-Resistant Human Breast Cancer Cell Subtypes: Convergence on the ROS/SUMO Pathway and Its Effects on xCT Expression and System xc- Activity
Katja Linher-Melville, Mina G Nashed, Robert G Ungard, et al.
ACS Medicinal Chemistry Letters
|
January 19, 2011
Identification of Purine-Scaffold Small-Molecule Inhibitors of Stat3 Activation by QSAR Studies
Vijay M Shahani, Peibin Yue, Sina Haftchenary, et al.
ACS Medicinal Chemistry Letters
|
October 18, 2023
Retraction of "Identification of Purine-Scaffold Small-Molecule Inhibitors of Stat3 Activation by QSAR Studies"
Vijay M Shahani, Peibin Yue, Sina Haftchenary, et al.
Bioorganic & Medicinal Chemistry
|
July 2, 2013
A 2,6,9-hetero-trisubstituted purine inhibitor exhibits potent biological effects against multiple myeloma cells
Vijay M Shahani, Daniel P Ball, Allan V Ramos, et al.
ACS Medicinal Chemistry Letters
|
September 24, 2015
Identification of Bidentate Salicylic Acid Inhibitors of PTP1B
Sina Haftchenary, Andriana O Jouk, Isabelle Aubry, et al.
Therapeutic Advances in Medical Oncology
|
March 2, 2023
Quality of life with ribociclib <i>versus</i> abemaciclib as first-line treatment of HR+/HER2- advanced breast cancer: a matching-adjusted indirect comparison
Hope S Rugo, Victoria Harmer, Joyce O'Shaughnessy, et al.
Page
of 2